Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch

Vanda Pharmaceuticals Inc.

2026-Q1 EPS reported -$0.82 revenue$51,718,000

Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.
NEREUS (tradipitant) launched via direct-to-consumer platform; first new motion sickness drug in 40+ years.
FY2026 revenue guidance raised to $240-290M from $230-260M, including $10-30M from NEREUS.
Net loss $48.6M ($0.82 diluted EPS) vs loss $29.5M ($0.50) in Q1 2025.
BYSANTI (milsaperidone) received FDA approval Feb 20 for bipolar I and schizophrenia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $51.7 million, net income net loss of $48.6 million (diluted loss per share of $0.82), EPS (diluted loss per share of $0.82). Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $51.7 million
Net income: net loss of $48.6 million (diluted loss per share of $0.82)
EPS: (diluted loss per share of $0.82)
Guidance: raised
Result: reported results

Exact text from the filing

pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9

View on SEC.gov

Browse all earnings releases →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.